FDA approves Novo Nordisk’s once-weekly insulinnews2026-03-27T13:43:46+00:00March 27th, 2026|Endpoints News|
AstraZeneca’s in vivo CAR-T led to early responses, but one death in China trialnews2026-03-27T12:00:35+00:00March 27th, 2026|Endpoints News|
Novartis to spend up to $2B on Excellergy and its next-gen Xolair candidatenews2026-03-27T11:21:39+00:00March 27th, 2026|Endpoints News|
Recursion appoints former Exelixis CMO; More executive moves at Incytenews2026-03-27T11:00:13+00:00March 27th, 2026|Endpoints News|
AstraZeneca’s COPD antibody gets Phase 3 wins in broader-than-expected populationnews2026-03-27T10:46:08+00:00March 27th, 2026|Endpoints News|
Top HHS official makes impassioned pitch to take on China biotechnews2026-03-27T05:00:45+00:00March 27th, 2026|Endpoints News|
Biopharma industry pushes back on FDA’s ‘America First’ user fee proposalsnews2026-03-26T17:46:16+00:00March 26th, 2026|Endpoints News|
Recordati says it’s received a $12B+ takeover bidnews2026-03-26T17:06:08+00:00March 26th, 2026|Endpoints News|
UCB picks Georgia for $2B biologics site; AbbVie exec visits China news2026-03-26T16:36:26+00:00March 26th, 2026|Endpoints News|
